Nexalin Technology, Inc. (NXL) News
Track canonical SquawkNews coverage tagged to NXL, Nexalin Technology, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.06% to 50,936.24 while the NASDAQ rose 0.37% to 26,960.69. The S&P 500 also rose, gai
LIVE | Oct 01, 2026, 05:54 PM UTC
L
Nexalin Technology, Inc. (NXL) Names DiTota Senior Strategic Advisor for Global Commercialization
Nexalin Technology appointed neuromodulation veteran Robert DiTota as Senior Strategic Advisor, Global Commercialization, to guide distribution and go-to-market for its DIFS platform in approved markets and future U.S./E
NEWS | Sep 29, 2026, 01:08 PM UTC
L
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
Appointment as Senior Strategic Advisor marks the Company’s expansion from clinical development toward commercialization of its DIFS™ platform in the United States, Europe and South AmericaDiTota spent over two decades i
NEWS | Sep 29, 2026, 01:08 PM UTC
L
Nexalin Technology DiTota's Appointment Effective Sept. 15 >NXL
Nexalin Technology DiTota's Appointment Effective Sept. 15 >NXL
NEWS | Sep 29, 2026, 01:02 PM UTC
L
Nexalin Technology Appoints Robert DiTota Senior Strategic Advisor >NXL
Nexalin Technology Appoints Robert DiTota Senior Strategic Advisor >NXL
NEWS | Sep 29, 2026, 01:01 PM UTC
L
Nexalin Technology Disclosed Failure to Satisfy a Continued Listing Rule or Standard
On September 25, 2026, the company received a Nasdaq Hearings Panel notice granting continued listing subject to meeting the $1.00 minimum bid price by September 28, 2026 and the $2.5 million stockholders' equity require
NEWS | Sep 28, 2026, 09:26 PM UTC
L
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
SYDNEY, Sept. 25, 2026 // -- Nuix (ASX:NXL), a global leader in investigative analytics and intelligence software, announced it has been named a Disruptor in the Risk Infrastructure category of the Chartis RiskTech100® 2
NEWS | Sep 25, 2026, 12:35 AM UTC
L
Greenlight Ventures discloses 5.6% stake in Nexalin Technology
Greenlight Ventures, LLC disclosed a 5.6% stake in Nexalin Technology, Inc.'s common stock. The filing was accepted Sep. 03, 2026, after stock was issued as non-cash consideration for Nexalin's purchase of PONM.
EQUITY | Sep 03, 2026, 05:39 PM UTC
L
Nexalin Technology reports secondary analysis improvements in Alzheimer’s trial data
Nexalin Technology said further ADAS-Cog data analysis from its randomized, sham-controlled trial found improvements tied to memory domains in Alzheimer’s patients. The Company plans to use ADAS-Cog subscale results for
EQUITY | Sep 03, 2026, 12:37 PM UTC
L
Nexalin says Carolyn Shelton exits senior vice president role
Nexalin said Carolyn Shelton departed as Senior Vice President of Quality, Regulatory and Clinical Affairs, effective August 28, 2026, under a separation agreement covering bonus and option vesting.
REGULATION | Sep 02, 2026, 09:05 PM UTC
L
Nexalin Technology announces reverse stock split
Nexalin Technology announced a reverse stock split.
EQUITY | Aug 27, 2026, 11:27 AM UTC
L
NXL: Wins Award
Nexalin Technology's investigator receives Young Researcher Award for evaluating the company's DIFS platform
EQUITY | Jun 23, 2026, 12:30 PM UTC